Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase EARLY_PHASE1 2Phase 1 2Phase 4 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 4Breast 4Sarcoma 3Genitourinary 3Thoracic 2Dermatologic 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Other 1Gynecologic 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Recurrent 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Hydroxychloroquine × Genitourinary × Clear all
NCT05036226 2026-05-13

COAST

Medical University of South Carolina

Phase 1/2 Recruiting
76 enrolled
GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

NCT03513211 2023-11-22

HITMAN-PC

St Vincent's Hospital, Sydney

Phase 1/2 Completed
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT01550367 2020-01-02

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

University of Pittsburgh

Phase 1/2 Completed
30 enrolled 20 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡